Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Council on “Clinical Innovation Network” Holds 1st Meeting, 7 Working Groups to Design Registries
The health ministry’s council to improve the environment for clinical development held its first meeting on August 20 to discuss the creation of what is called the “clinical innovation network,” a patient-registry-based infrastructure aimed at facilitating clinical trials in Japan.…
To read the full story
Related Article
- MHLW to Draw Up Guidelines on Registry Data Use for Submissions: Clinical Innovation Network Initiative
March 15, 2019
- Centralized Support Unit Needed for “Clinical Innovation Network”: JPMA’s Teshirogi
April 8, 2016
- MHLW Seeks 30.7 Trillion Yen in FY2016 Budget, 104.3 Billion for Drug, Healthcare Initiatives
August 27, 2015
- MHLW to Seek FY2016 Budgets for Genomic Data Collection, Registry-Based Trial Platform
August 20, 2015
- NCC Eyes Trial Enrollment of 150 Rare Cancer Patients under Registry Initiative
July 3, 2015
- Govt OKs Economic Growth Strategy, Regulatory Reform Plan
July 1, 2015
- Japan Cabinet OKs Fiscal Policy Guidelines, Marking Dawn of “80% Generic” Era
July 1, 2015
- LDP Weighs Clinical Development Infrastructure Utilizing Patient Registry
April 24, 2015
REGULATORY
- Nakai Tapped as MHLW’s Top Pharmacy Officer; Ohara to Steer Drug Pricing Reform
August 7, 2026
- Sarclisa SC, Joenja, Kineret, and 7 More Drugs Bound for NHI Listing
August 6, 2026
- Tepezza Price Cut Set at 5.5% under Japan’s CEA Scheme
August 6, 2026
- Dupixent Faces Fourth Re-Pricing under Japan’s SPA-SSS
August 6, 2026
- Chuikyo Clears NHI Listing for Oncolys’ Telomelysin
August 6, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…